BBOT
BridgeBio Oncology Therapeutics, Inc.
Next earnings Jul 29, 2026 · consensus $-0.57 EPS
Last earnings +3.0% on 2026-05-12
$7.40
▼ -3.77%$7.40▼ -30.52%
over 1Y
L $7.12EODHDH $13.73
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.8%
1W-6.0%
1M-13.2%
3M-16.7%
YTD-39.8%
1Y-30.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.09x).
Return on equity -32.6% · latest
BridgeBio Oncology Therapeutics, Inc. shows limited reported revenue, and -32.6% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$41.7K | -$80.9M | -$146M |
| Net income | -$41.7K | -$74.3M | -$134M |
| Diluted EPS | — | -$5,756.41 | -$4.30 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$219M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-22.6%
FCF yield-19.3%
Quality & risk
ROIC (est.)-28.0%
Free cash flow-$115M
Total debt—
Net cash$374M
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-22
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K Officer / director change2026-04-29
- DEF 14A Proxy statement2026-04-28
- 8-K Officer / director change2026-04-23
- 8-K Officer / director change2026-03-26
- 8-K Earnings results2026-03-05
- 10-K Annual report2026-03-05
Recent filings
all on EDGAR ↗424B3Filing2026-06-22open ↗8-KPeriod ending 2026-06-162026-06-22open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗424B3Filing2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗
Frequently asked
- Is BridgeBio Oncology Therapeutics, Inc. (BBOT) a buy?
- BBOT currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.09x).
- What is BridgeBio Oncology Therapeutics, Inc.'s quality score?
- BBOT scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001869105, latest 10-Q filed 2026-05-12) · EODHD · as of 6/22/2026, 11:31:54 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.